Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.857%)
Open: 17.50
High: 0.00
Low: 0.00
Prev. Close: 17.75
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Mar 2023 10:31

RNS Number : 0102S
Destiny Pharma PLC
06 March 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Destiny Pharma Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Unicorn Asset Management Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Unicorn AIM VCT plc

City and country of registered office (if applicable)

Newton Abbot, United Kingdom

5. Date on which the threshold was crossed or reachedvi:

01 March 2023

6. Date on which issuer notified (DD/MM/YYYY):

03 March 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

4.65%

4.65%

4,076,923

Position of previous notification (if

applicable)

5.14%

5.14%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares

GB00BDHSP575

4,076,923

4.65%

SUBTOTAL 8. A

4,076,923

4.65%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Figures are based on total voting rights of 87,742,819

 

Place of completion

Unicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU

Date of completion

03 March 2023

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAEDKEDEDEFA
Date   Source Headline
25th Apr 20247:00 amRNSFull year results and review of strategic options
8th Apr 20247:00 amRNSNotice of Full Year Results
19th Mar 20242:47 pmRNSExercise of Options and Total Voting Rights
31st Jan 20247:00 amRNSClinical development update
22nd Jan 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
4th Jan 20247:00 amRNSYear End Business Update
20th Oct 20237:00 amRNSGrant of Share Options
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
17th Oct 20237:01 amRNSXF Pipeline Update Meeting
17th Oct 20237:00 amRNSPublication of new microbiological data for XF-73
10th Oct 20237:00 amRNSDirector/PDMR Shareholding
4th Oct 202312:34 pmRNSDirector/PDMR Shareholding
27th Sep 20237:00 amRNSNotice of XF Pipeline Update Meeting
20th Sep 20237:00 amRNSInterim Results
23rd Aug 20237:00 amRNSNotice of Interim Results
31st Jul 202312:01 pmRNSPublication of new data for XF-73
25th Jul 20237:00 amRNSAppointment of new Chairman
19th Jul 202312:55 pmRNSBoard changes including appointment of new CEO
7th Jul 20237:00 amRNSExercise of Options and Total Voting Rights
6th Jul 20237:00 amRNSPositive findings from recent SAB meeting
29th Jun 20237:00 amRNSBusiness Update
26th May 20233:27 pmRNSDirector/PDMR Shareholding
26th May 20237:00 amRNSDirector Dealing
25th May 202312:23 pmRNSResult of Annual General Meeting
25th May 20237:00 amRNSDr Debra Barker Appointed Interim CEO
12th May 202312:24 pmRNSGrant of Share Options
2nd May 20237:00 amRNSPositive results from SPOR-COV® research
26th Apr 20234:10 pmRNSPosting of Annual Report and Notice of AGM
26th Apr 202310:05 amRNSExercise of Options and Total Voting Rights
13th Apr 20237:00 amRNSAudited results for year ended 31 December 2022
4th Apr 20237:00 amRNSLandmark data published on NTCD-M3
3rd Apr 20237:00 amRNSNotice of Results and Investor Presentation
24th Mar 20237:00 amRNSLandmark XF-73 Phase 2 data published in journal
16th Mar 20233:29 pmRNSResult of General Meeting and Total Voting Rights
15th Mar 20234:02 pmRNSResult of Open Offer
6th Mar 202310:50 amRNSExercise of Options and Total Voting Rights
6th Mar 202310:31 amRNSHolding(s) in Company
28th Feb 20233:55 pmRNSPosting of Circular and Notice of General Meeting
27th Feb 20234:30 pmRNSDirector/PDMR Shareholding
24th Feb 20231:32 pmRNSIssue of Equity
24th Feb 20231:32 pmRNSAgreement with Sebela Pharmaceutical for NTCD-M3
24th Feb 202311:00 amRNSPrice Monitoring Extension
31st Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 202310:10 amRNSExercise of Options and Total Voting Rights
25th Jan 20237:00 amRNSUS Center for Disease Control review paper
22nd Dec 20229:05 amRNSSecond Price Monitoring Extn
22nd Dec 20229:00 amRNSPrice Monitoring Extension
22nd Dec 20227:00 amRNSYear End Trading Update
7th Dec 20227:00 amRNSFDA/CDC highlight need for infection preventions
7th Dec 20227:00 amRNSXF-73 Nasal final Phase 3 development plans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.